AI + blood test could spot lung cancer earlier in smokers

NCT ID NCT06320184

Ongoing Knowledge-focused Sponsor: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether combining artificial intelligence with blood biomarkers and CT scan features can better predict lung cancer risk in heavy smokers. Researchers will analyze data from 650 participants to develop a risk model that improves screening accuracy and reduces unnecessary follow-ups. The goal is to make lung cancer screening more precise and effective.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Artificial intelligence risk model combining blood biomarkers, radiologic parameters, and clinical features
What this could lead to: If successful, this could lead to a more accurate, non-invasive way to identify who is at high risk for lung cancer, reducing unnecessary procedures and catching cancers earlier.
What could go wrong: This is an observational study, not a treatment trial. The AI model may not perform as well in real-world settings, and results may take years to validate.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BLOOD BIOMARKERS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

lung cancer lung neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BLOOD BIOMARKERS LUNG CANCER

Contacts and locations

Locations

Fondazione IRCCS Istituto Nazionale dei Tumori

Milan, 20133, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.